.
MergerLinks Header Logo

Announced

Completed

DCVC and Temasek led a $430m Series D funding round in Pivot Bio.

Financials

Edit Data
Transaction Value£312m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Minority

Fertilizers

crop nutrition

agricultural technology

agtech

agriculture

United States

Private Equity

Venture Capital

Cross Border

Friendly

Private

Acquisition

Completed

Synopsis

Edit

DCVC, a venture capital firm, and Temasek, Singapore’s sovereign fund, led a $430m Series D funding round in Pivot Bio, a provider of pioneering game-changing advances in crop nutrition. Additional investors included Generation Investment, G2 Venture, Rockefeller Capital, Breakthrough Energy, Continental Grain, Prelude Ventures, Pavilion Capital, Bunge Ventures, Tekfen Ventures and individual investor Roger Underwood. “Pivot Bio exemplifies the power of DeepTech solutions to create equitable and profitable outcomes for all stakeholders in immense industries like agriculture. Farmers are able to grow more crops to feed more people, more cost-effectively, while being even better stewards of their land and water. Societies benefit from both more abundant food and more climate-resilient and sustainable agriculture. Pivot Bio has delivered the kind of win-win-win breakthrough DCVC is honored to back, and on which we are focused as a firm,” Matt Ocko, DCVC Co-Managing Partner.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US